Cost Considerations for the Application of Continuous Processing
02nd October 2019 | 3:00 PM India Standard Time/ 10:30 AM GMT | Narasimha Rao Nedunuri, CEO of CLONZ Biotech and Tania Pereira Chilima, Product Manager at Univercells |WATCH FOR FREE
- Cost contribution of continuous manufacturing both in operational and capital expenditure in Monoclonal antibody production.
- Evaluating cost of production per gram conventional fed batch vs continuous process.
- Key considerations for adapting continuous process for the production of Biosimilar MAbs.
Presented by Narasimha Rao Nedunuri, CEO of CLONZ Biotech
And Tania Pereira Chilima, Product Manager at Univercells
Tania Pereira Chilima is a Product Manager at Univercells, responsible for the NevoLine platform for cost-effective viral production. She completed her Bachelors’ degree in Biochemical engineering with focus on protein manufacture at the University College London. She was then awarded an Engineering doctorate, also at the University College London, looking at building and applying decisional tools to help guide the cell therapy industry in selecting commercialization strategies (process, facility design, reimbursement strategies etc.). Her post-doc was sponsored by the Bill & Melinda Gates Foundation, focused on identifying the optimal manufacturing strategies to deliver low cost vaccines.
Univercells is a technology company offering novel biomanufacturing platforms, aimed at increasing the availability and affordability of biologics – recombinant proteins and vaccines – for all. Univercells designs innovative production processes to significantly decrease the size of the necessary equipment and facility, for a lower capital and operational cost.
The company’s process intensification and integration technology entails smaller footprint and unit cost while offering flexible capabilities, from small to large batches.
Deployment of affordable production units enables ‘in-country, for-country’ biologics production, creating value for manufacturers and healthcare systems with cost efficiency and local supply while increasing patients’ access to healthcare.
Univercells was founded in 2013 by experienced entrepreneurs Hugues Bultot, CEO, and José Castillo, CTO, who bring close to 25 years of expertise in the biotechnology and life sciences sectors. Headquartered in Gosselies (Belgium), Univercells benefits from support from the Walloon region, and received €3 million from Takeda in 2015. Most recently, the company was awarded a $12 million grant from the Bill & Melinda Gates Foundation.